Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until March 2018 he was President and CEO of Boehringer Ingelheim USA. Paul Fonteyne follows Prof. em. Dr. Norbert Thom, who resigned at the 2018 Annual General Meeting.
Paul Fonteyne is currently Chairman of Boehringer-Ingelheim USA. He served as President and CEO of Boehringer Ingelheim, USA and as US country managing director since 2012 until March of 2018. In this role, Paul Fonteyne led the team that ensures the company’s success in the US, for all of Boehringer Ingelheim businesses including Human Pharmaceuticals, Animal Health and Bio Manufacturing. Paul Fonteyne joined Boehringer Ingelheim in 2003 and was responsible for the Human Pharmaceuticals business in the US from 2003 to 2008. He moved to Germany to lead the global marketing team for the global Human Pharmaceuticals business from 2008 to 2011. Prior to joining Boehringer Ingelheim, Paul Fonteyne held various marketing and sales positions at Abbott Labs and Merck & Co. Inc. Born in Brussels, he holds dual citizenship in both the US and Belgium. He earned an M.S. in Chemical Engineering from University of Brussels in 1985 and an M.B.A. from Carnegie Mellon University in the USA in 1987. Paul Fonteyne is a past board member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and current board member of ResTORbio, and Gelesis, both Boston-based clinical stage biotechnology companies. Paul Fonteyne resides with his family in Westport, Connecticut, USA.
“With his many years of international experience, Paul Fonteyne will enrich the expansion strategy and further market launches of the mylife™ YpsoPump® globally and especially in the USA and make a significant contribution to the success of the Ypsomed Group. At the same time I would like to thank Norbert Thom for his many years of successful service for us. With his profound knowledge in the areas of organisational theory as well as knowledge and innovation management, he has repeatedly challenged and advanced us,"
comments Simon Michel, CEO of Ypsomed, the change on the Board of Directors.
Prof. em. Dr. Norbert Thom was a member of the Board of Directors and the Compensation Committee of the Ypsomed Group from 2005 to 2018 and accompanied strong sales and earnings growth.